Instructional BiologyBiomanufacturing has a quiet, longstanding tradeoff baked into almost every process design decision: pathogen safety versus structural integrity. Make a process aggressive enough to reliably eliminate pathogens — which, for decades, has generally meant heat, and a lot of it — and you risk destroying the very molecular structure that made the material worth manufacturing in the first place. Ease off the heat to protect that structure, and you risk an unacceptable safety margin. For most of the industry's history, that tradeoff has been treated as a fact of the process rather than a design choice worth revisiting.
Introducing MHFBP
The Markosian High-Fidelity Bio-Processing Protocol is our answer to that tradeoff: a controlled, lower-temperature processing approach paired with non-thermal methods for pathogen management, built on the premise that specific-pathogen-free sourcing changes how much force is actually necessary to reach a safe outcome — as opposed to how much has simply been conventional. Rather than defaulting to heat because it's the most familiar lever available, MHFBP treats the safety-versus-structure tradeoff as something to engineer around, not something to accept.
We think this matters beyond our own programs. It's a genuine open question for biomanufacturing more broadly: how much structurally valuable material has legacy processing quietly discarded over the years, not because it had to, but because the alternative required more careful, more deliberate — and yes, slower — process design than the industry had historically been willing to invest in?
Why this is a manufacturing story as much as a science story
It's easy to frame protein structure preservation as a purely scientific problem, but the reason it hasn't already been solved industry-wide is mostly economic: lower-temperature, higher-fidelity processing is slower, and slower has historically meant less competitive at scale. MHFBP doesn't sidestep that economics — it's a genuinely harder, more deliberate process than high-heat sterilization, and we don't pretend otherwise. What we think has changed is the calculation on the other side of that tradeoff: as the value of structurally intact biological material becomes better understood, the case for investing in a slower, more careful process gets stronger.
We see this as the leading edge of a broader shift in biomanufacturing — one where preserving information, not just producing volume, becomes a competitive axis in its own right.
Go deeper
The full technical thesis behind MHFBP, and why the tradeoff it addresses was never actually fixed.